# Minimal inhibitory concentrations of sulbactam/ampicillin against drug sensitive and drug resistant isolates of *Mycobacterium tuberculosis*

C. N. Paramasivan\*, P. Venkataraman and D. Herbert

Tuberculosis Research Centre, Indian Council of Medical Research, Spur Tank Road, Chetput, Madras 600 031, India and Department of Bacteriology, Tuberculosis Research Centre, Indian Council of Medical Research, Spur Tank Road, Chetput, Madras, 600 031, India (\*Reprint address)

Key words: Mycobacterium tuberculosis, sulbactam/ampicillin, in vitro antimicrobial testing, minimal inhibitory concentration

## Abstract

A total of 92 isolates of *Mycobacteriurn tuberculosis* consisting of equal numbers of sensitive and resistant strains was tested for their susceptibility to sulbactam and ampicillin (in the ratio of 1:2) on Lowenstein-Jensen (LJ) and 7H11 agar media. The geometric mean MIC was 63.97  $\mu$ g/ml for the drug sensitive strains and 65.92  $\mu$ g/ml for the resistant strains, and the overall mean was 65.01  $\mu$ g/ml. The high MIC on LJ medium could be attributed to the higher protein content which resulted in greater binding of sulbactam/ampicillin. On the other hand, the geometric mean MIC on 7H11 medium was 26.73  $\mu$ g/ml for sensitive strains and 23.82  $\mu$ g/ml for resistant strains; the overall mean being 25.23  $\mu$ g/ml. Although these MICs of sulbactam-ampicillin are higher than those reported earlier, they can be easily achieved in serum. Further studies on experimental tuberculosis and in humans will be needed to prove the efficacy of sulbactam/ampicillin in the treatment of patients with multidrug resistant tuberculosis.

## Introduction

Multidrug-resistant tuberculosis (MDR-TB) is rapidly emerging as a major problem in the treatment of tuberculosis both in the developed countries and in the developing countries (Riley, 1993; Nagpaul, 1994). The prognosis for chemotherapy in tuberculosis patients with *Mycobacterium tuberculosis* resistant to rifampicin and isoniazid is poor (Hong Kong Chest Services/British Medical Research Council, 1992; Goble *et al.*, 1993; Rema Mathew *et al.*, 1993). In these patients administration of effective treatment with regimens containing at least two or three drugs to which the organisms are sensitive is essential for curing the disease and blocking the transmission (Goble *et al.*, 1993).

A large number of new drugs has been introduced in recent years for the treatment of bacterial, parasitic, fungal and viral diseases. In contrast, very few major new antituberculosis agents have become available since rifampicin was introduced in the early 1970s (O'Brien and Snider, 1985). The current TB epidemic associated with HIV infection and the occurrence of MDR-TB have led to the need for rapid development of new antituberculosis drugs and it has become necessary to screen new drugs for antituberculosis activity (Mitchison *et al.*, 1988; Parenti, 1989). Hence, systematic evaluation of new antituberculosis drugs is being undertaken at this Centre (Selvakumar *et al.*, 1992; Venkataraman *et al.*, 1992a,b,c; Herbert *et al.*, 1997; Kamala *et al.*, 1997).

Even though the  $\beta$ -lactam drugs are ineffective against mycobacteria which are  $\beta$ -lactamase producing organisms, combinations of  $\beta$ -lactam antibiotics with  $\beta$ -lactamase inhibitors have been shown to have activity against these organisms (Casal *et al.*, 1987; Sorg and Cynamon, 1987; Parenti, 1989; Nadler *et al.*, 1991). Among these, sulbactam/ampicillin (SA) has been shown to have a minimal inhibitory concentration (MIC) of 8 µg/ml against *M. tuberculosis* isolates (Sorg and Cynamon, 1987).

The present study was carried out to determine the MICs of SA for drug sensitive and drug resistant *M. tuberculosis* isolates from southern Indian patients both on Lowenstein-Jensen (LJ) and Middlebrooks 7H11 media to see whether the high protein content of LJ medium would have any effect on the MICs.

# Materials and methods

## **Bacterial strains**

A total number of 46 *Mycobacterium tuberculosis* isolates from tuberculosis patients admitted to various clinical trials at the Tuberculosis Research Centre (TRC), Madras, which were sensitive to streptomycin (S), isoniazid (H) and rifampicin (R) and 46 isolates which were SHR/HR resistant were used in the study.

# Drug containing medium

Pure powders of sulbactam and ampicillin (kindly provided by Unichem Laboratories Ltd, India) were dissolved in sterile distilled water and added to LJ medium before inspissation of the slopes and sterile 7H11 medium containing oleic acid-albumin-dextrose complex (OADC) enrichment before pouring the plates to get final concentrations of 1, 2, 4, 8, 16, 32, 64 and 128  $\mu$ g/ml ampicillin with a sulbactam:ampicillin ratio of 1:2.

## Sensitivity testing

From 2- to 3-week-old cultures of each *M. tuberculosis* strain on LJ, standard bacterial suspensions of 4 mg/ml were prepared in bijoux bottles with sterile distilled water and beads and shaken for uniform distribution. One loopful each of the suspension was inoculated onto two drug-free LJ slopes and one drug containing-LJ slope of each concentration with a 3 mm diameter loop, and 10  $\mu$ l each was inoculated onto duplicate sectors of drug-free and drug-containing 7H11 plates

with a micropipette. The inoculated media, of 7H11 plates in polythene bags, were incubated at 37°C and read at the end of 4 weeks. The lowest concentration of the drug which inhibited growth to less than twenty colonies compared with at least numerous discrete colonies (++ growth) on drug-free medium was taken as the minimal inhibitory concentration (MIC).

#### Results

The frequency distribution of MICs of SA on LJ medium is presented in Table 1. The MICs ranged from 8 to >128 µg/ml. For the majority of the strains, SA had high MICs on LJ medium. Of the 92 strains tested on LJ medium, the MIC was >64 µg/ml for 66 (71.7%) and the overall geometric mean MIC (GM) was 65.01 µg/ml. The GM was 63.97 µg/ml for the 46 drug sensitive strains and 65.92 µg/ml for the 46 drug resistant strains. The difference in GM between the drug sensitive and the drug resistant strains was not significant (p >0.5).

The frequency distribution of MICs of SA on 7H11 medium is shown in Table 2. The MICs of SA were lower on 7H11 compared with that on LJ media and ranged from 8 to 64 µg/ml. The overall GM for the 64 strains tested on 7H11 was 25.23 µg/ml which was significantly lower than that on LJ medium (p <0.001). For none of the strains tested, the MIC was >64 µg/ml and for 47 of the 64 strains (73.4%) the MIC was  $\leq$  32 µg/ml. The GM was 26.73 µg/ml for the 31 drug sensitive strains and 23.82 µg/ml for the 33 drug resistant strains. Again, this difference in GM of drug sensitive and drug resistant strains was not significant (p >0.5).

<i>M. tuberculosis</i> isolates	MIC( 8	(µg/ml c 16	of ampic 32	illin) of 64	SA on I 128	_J: >128	Total	GM
SHR sensitive	2	1	8	20	14	1	46	63.97
SHR/HR sensitive	0	2	13	14	15	2	46	65.92
Total	2	3	21	34	29	3	92	65.01

**Table 1** Frequency distribution for MIC of sulbactam/ampicillin in  $\mu$ g/ml of ampicillin against SHR sensitive and SHR/HR resistant isolates of *M. tuberculosis* on LJ medium

137 In vitro activity of sulbactam/ampicillin against M. tuberculosis

**Table 2** Frequency distribution for MIC of sulbactam/ampicillin in  $\mu$ g/ml of ampicillin against SHR sensitive and SHR/HR resistant isolates of *M. tuberculosis* on 7H11 medium

<i>M. tuberculosis</i> isolates	MIC( 8	µg/ml o 16	f ampici 32	illin) of 3 64	SA on 7H11: 128	Total	GM
HR sensitive	5	8	8	10	0	31	26.73
SHR/HR resistant	6	9	11	7	0	33	23.82
Total	11	17	19	17	0	64	25.23

## Discussion

Abraham et al. (1941) observed that *M*. tuberculosis was not inhibited *in vitro* by high concentrations of penicillin. The penicillinase activity of *M. tuberculosis* was subsequently identified (Hand and Bains, 1949; Soltys, 1952). Later, this penicillinase was shown to be a  $\beta$ -lactamase in studies on the effect of  $\beta$ -lactamase susceptible and resistant antibiotics on the *in vitro* growth of *M. tuberculosis* (Kasik, 1964). It was also shown that a combination of  $\beta$ -lactamase stable oxacillin with penicillin was more effective than either drug alone in inhibiting mycobacterial growth and that this penicillin-sparing effect was due to  $\beta$ -lactamase inhibition (Kasik *et al*, 1967). This activity of penicillin+ lactamase inhibitor combination on *M. tuberculosis* was also demonstrated in a murine model of tuberculosis (Kasik *et al.*, 1966).

Clavulanic acid and sulbactam are specific inhibitors of  $\beta$ -lactamase which are currently used clinically to protect  $\beta$ -lactamase susceptible antibiotics (Bush, 1988). Of these two, clavulanic acid is a natural product while sulbactam was developed later (Brown *et al.*, 1976; English *et al.*, 1978). Augmentin is an oral preparation of clavulanic acid in combination with amoxicillin. Timentin is a parental preparation of clavulanic acid with ticarcillin while Sulbacin is a parental preparation of sulbactam with ampicillin. Ticarcillin in combination with clavulanic acid has been studied *in vitro* against various mycobacteria (Casal *et al.*, 1989). All the *M. tuberculosis*, *M. bovis* and *M. africanurn* strains were susceptible at 32 µg/rnl or less of ticarcillin in combination with 5 µg/ml of clavulanic acid. The MIC of amoxycillin/clavulanic acid against *M. tuberculosis* has been reported

138 Microbios

to be 4.4  $\mu$ g/ml and that of sulbactam/ampicillin to be 8.8  $\mu$ g/ml (Sorg and Cynamon, 1987) In mouse foot-pad, while amoxycillin clavulanic acid combination had no effect on the growth of *M. leprae*, the same concentration of SA was found to suppress their multiplication (Prabhakaran *et al.*, 1992).

In the present study, the mean MICs of SA against *the M. tuberculosis* were significantly lower when tested on 7H11 medium compared with LJ medium. This was probably due to the higher protein content and in turn higher binding of sulbactam and ampicillin in LJ medium. Protein binding in serum has been reported to be 28% for ampicillin and 38% for sulbactam (Wise, 1986). In connection with the results on 7H11 medium, the overall mean MIC of SA for all the *M. tuberculosis* strains tested was 25.23 µg/ml, with no significant difference between the GM of SHR/HR resistant and SHR sensitive strains indicating that cross resistance does not exist between SA and SHR.

The MICs of SA in the present work were higher than the MIC of 8  $\mu$ g/ml reported earlier by Sorg and Cynamon (1987). However, even these higher levels can be easily achieved in serum because peak serum concentrations of >90  $\mu$ g/ml of ampicillin have been reported after intravenous dosage regimen of 2 g of ampicillin and 1 g of sulbactam (Foulds *et al.*, 1983), and from 51-82  $\mu$ g/ml and > 15  $\mu$ g/ml of ampicillin, respectively, after intravenous and intramuscular administration of 1 g of ampicillin and 0.5 g of sulbactam (Foulds, 1986; Ripa *et al.*, 1990). The other favourable features of SA are that useful concentrations of SA can be achieved in pus, sputum and middle ear fluid. Moreover, penetration of SA into CSF is increased in patients with bacterial meningitis (Rodriguez *et al.*, 1986; Foulds, 1986) and this combination has been remarkably free of major side effects (Lees *et al.*, 1986).

Our investigation shows that SA could be useful in the treatment of tuberculosis, particularly in drug resistant patients. It has already been shown that the multiplication of *M. leprae* in foot pads of experimentally infected mice is suppressed by intramuscular administration of SA and that SA also inhibits the growth of drug resistant *M. leprae* which could grow in the presence of rifampicin or dapsone (Prabhakaran *et al.*, 1992). It has been shown that on log-phase cultures of *M. tuberculosis* in 7H9 liquid medium SA has bactericidal action similar to that of rifampicin and isoniazid (Herbert *et al.*, 1997). Further studies are required on the activity of SA on *M. tuberculosis* in mouse models and in tuberculosis patients.

#### Acknowledgement

Sulbactam and ampicillin were kindly provided by Unichem Laboratories Ltd, India.

139 In vitro activity of sulbactam/ampicillin against M. tuberculosis

#### References

ABRAHAM E. R, Chain E. and Fletcher C. M. 1941. Further observations on penicillin. *Lancet* **2** 177-88.

BROWN A. G., Butterworth D., Cole M., Hanscomb G., Hood J. D., Reading C. and Rolinson G. N. 1976. Naturally occurring ß-lactamase inhibitors with antibacterial activity. *J. Antibiot.* **29** 668-9.

BUSH K. 1988. ß-Lactamase inhibitors from laboratory to clinic. *Clin. Microbiol. Rev.* **1** 109-23.

CASAL M. J., Rodriguez F. C., Luna M. D. and Benavente M. *C. 1987. In vitro* susceptibility of *M. tuberculosis, M. africanum, M. bovis, M. avium, M. fortuitum* and *M. chelonei* to ticarcillin in combination with clavulanic acid. *Antimicrob. Agents Chemother.* **31** 132-3. ENGLISH A. R., Retsema J. A., Girard A. E., Lynch J. E. and Barth W. E. 1978. CP-45 899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterisation. *Antimicrob. Agents Chemother.* **14** 414-9.

FOULDS G. 1986. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev. Infect. Dis. 8 (Suppl 5) S503-11.

FOULDS G., Stankewich J. P., Marshall D. C., O'Brien M. M., Hayes S. L., Weidler D. J. and McMahon F. G. 1983. Pharmacokinetics of sulbactam in humans. *Antimicrob. Agents Chemother.* **23** 692-9.

GOBLE M., Iseman M. D., Madsen L. A., Waite D., Ackerson L. and Horsburgh R. Jr. 1993. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. *New Engl. J. Med.* **328** 527-32.

HAND C. N. and Bains S. 1949. The effect of penicillin on the tubercle bacillus. J. Path. Bact. 61 329-35.

HERBERT D., Paramasivan C. N., Venkatesan P., Kubendiran G., Prabhakar R. and Mitchison D. A. 1996. Evaluation of bactericidal action of ofloxacin and sulbactam/ampicillin, alone and in combination with rifampicin and isoniazid, on *M. tuberculosis in vitro. Antimicrob. Agents Chemother.* **40** 2296-9.

HONG KONG Chest Services/British Medical Research Council. 1992. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. *Tuberc. Lung. Dis.* **73** 57-67.

KAMALA T., Herbert D., Venkatesan P. and Paramasivan C. N. 1997. Minimal inhibitory concentrations of lomefloxacin and minocycline against drug sensitive and drug resistant isolates of *Mycobacterium tuberculosis* compared on LJ and 7H11. *Int. J. Leprosy* In press.

KASIK J. E. 1964. Activity of some semisynthetic penicillins on *Mycobacterium tuberculosis*. *In* Antimicrobial Agents and Chemotherapy. pp 315-20. American Society of Microbiology, Ann Arbor, Michigan, U.S.A.

KASIK J. E., Weber M., Winberg E. and Barclay W. R. 1966. The synergistic effect of dicloxacillin and penicillin G on murine tuberculosis. *Am. Rev. Respir. Dis.* **94** 260-1.

KASIK J. E., Weber M. and Freehill R J. 1967. The effect of the penicillinase resistant penicillins and other chemotherapeutic substances on the penicillinase of the R1Rv strain of *Mycobacteriurn tuberculosis. Am. Rev. Respir. Dis.* **95** 12-9.

LEES L., Milson J. A., Knirsch A. K. and Greenhalgh K. 1986. Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use. *Rev. Infect. Dis.* **8** S644-50.

MITCHISON D. A., Ellard G. A. and Grosset J. 1988. New antibacterial drugs for the treatment of mycobacterial disease in man. *Br. med. Bull.* **44** 757-74.

NADLER J. P., Berger J., Nord J. A., Cofsky R. and Saxena M. 1991. Amoxicillinclavulanic acid for treating drug resistant *Mycobacteriurn tuberculosis. Chest* **99** 1025-6. NAGPAUL D. R. 1994. Multidrug resistance in tuberculosis. *Ind. J. Tuberc.* **41** 1-2.

O'BRIEN R. J. and Snider D. E. Jr. 1985. Tuberculosis - old and new. Am. Rev. Respir. Dis. **131** 309-11.

PARENTIF. 1989. New experimental drugs for the treatment of tuberculosis. *Rev. Infect. Dis.* **11** (Suppl 2) S479-83.

PRABHAKARAN K., Harris E. B., Randhawa B. and Hastings R. C. 1992. Reversal of drug resistance in *Mycobacterium leprae* by ampicillin/sulbactam. *Microbios* **72** 137-42.

REMA M., Santha T., Parthasarathy R., Rajaram K., Paramasivan C. N., Janardhanam B., Somasundaram R R. and Prabhakar R. 1993. Response of patients with initially drug resistant organisms to treatment with short course chemotherapy. *Ind. J. Tuberc.* **40** *119-23.* 

RILEY L. W. 1993. Drug resistant tuberculosis. Clin. Infect. Dis. 17 (Suppl 2) S442-4.

RIPA S., Ferrante L. and Prenna M. 1990. Pharmacokinetics of sulbactam/ampicillin in humans after intravenous and intramuscular injection. *Chemother.* **36** 185-92.

RODRIGUEZ W. J., Khan W. N., Ping J., Feris J., Harmon S., Gold B. G. and Ahmad S. 1986. Sulbactam/ampicillin for the treatment of meningitis in infants and children. Rev. *Infect. Dis.* **8** S620-9.

SELVAKUMAR N., Vanajakumar K., Acharyulu G. S., Fathima Rehman, Paramasivan C. N. and Prabhakar R. 1992. Tuberactinomycin susceptibility of *M. tuberculosis* isolated from South India. *Ind. J. Med. Res.* **95** 101-4.

SOLTYS M. A. 1952. The effect of penicillin on mycobacteria *in vitro* and *in vivo*. *Tubercle* **33** 120-5.

SORG T. B. and Cynamon M. H. 1987. Comparison of four beta lactamase inhibitors in combination with ampicillin against *Mycobacteriurn tuberculosis*. J. Antimicrob. Chemother. **19** 59-64.

VENKATARAMAN P., Paramasivan C. N. and Prabhakar R. 1992a. *In vitro* activity of rifampicin, rifapentine and rifabutin against South Indian isolates of *M. tuberculosis. Ind. J. Tuberc.* **40** 17-20.

VENKATARAMAN P., Paramasivan C. N. and Prabhakar R. 1992b. *In vitro* activity of capreomycin and ciprofloxacin against South Indian isolates of *M. tuberculosis. Ind. J. Tuberc.* **40** 21-4.

VENKATARAMAN P., Paramasivan C. N. and Prabhakar R. 1992c. In vitro activity of ciprofloxacin and ofloxacin against South Indian isolates of *M. tuberculosis. Ind. J. Tuberc.* **41** 87-90.

WISE R. 1986. The clinical relevance of protein binding and tissue concentration in antimicrobial therapy. *Clin. Pharmacokinetics* **11** 583-7.

Accepted 3 February 1997

## News to authors

Manuscripts will be refereed, processed and published rapidly providing the typescript and illustrations have been carefully and accurately prepared in the correct style of each journal.

By following the style of our biomedical journals meticulously you can obtain the advantages of some of the most rapid publication rates for research papers available anywhere. However, a prerequisite is that manuscripts must be impeccably presented in the journal style.

Read the leaflets prepared for authors, entitled information for contributors and *Photographic illustrations,* and send manuscripts for the international biomedical journals MICROBIOS, CYTOBIOS and *BIOMEDICAL LETTERS,* to Dr Stuart Anderson, Executive Editor, The Faculty Press, 88 Regent Street, Cambridge CB2 IDP, England.

- MICROBIOS is a biomedical research journal, established in 1969, which is concerned with all aspects of Bacteriology and Microbiology. Issues are published every three to four weeks comprising four volumes per annum.
- \* BIOMEDICAL LETTERS is an international journal for rapid publication of medical, biomedical, and neuroscience research papers, and was first published in 1976. Issues are despatched bimonthly.
- \* CYTOBIOS was founded in 1969, and is a biomedical journal for research papers into all aspects of cell science and genetics. Issues are published monthly in four volumes per annum.
- \* Manuscripts are peer reviewed.
- \* Fifty reprints are provided free to the first named author, although postage is extra.
- \* Worldwide distribution, so authors invariably receive many requests for reprints.
- \* Abstracted in CURRENT CONTENTS and all the leading abstracting journals.
- \* Subscription rates and leaflets for authors are available from the publishers.

The Faculty Press 88 Regent Street Cambridge CB2 1DP England

# **MICROBIOS**

is an international biomedical research journal, established in 1969, which is devoted to fundamental studies of viruses, bacteria, microfungi, microscopic algae, and protozoa. it is concerned with all aspects of micro-organisms, but lays particular emphasis upon chemical microbiology.

Original observations are accepted on the applications of microbiology in the fields of pharmaceutical and chemical production; food manufacture and spoilage; public health and sanitation; biodeterioration; pharmacology and immunology.

Papers on the organization and metabolic activities of micro-organisms are published, as well as work on cell-virus interactions. Manuscripts which are especially welcome are those dealing with the chemical anatomy of micro-organisms, and the biochemical and biophysical factors that affect microbial activity.

The subscription rate for 1997 will be £395.00 sterling

## CYTOBIOS

is a transworld biomedical research journal, established in 1969, which publishes original investigations into all aspects of cell organization. Contributions will be accepted on the behaviour, structure and function of animal and plant cells, including studies on extracellular products and subcellular organelles.

The journal emphasizes work at chemical and molecular levels. It publishes original papers on cytogenetics; cell division and growth; cell physiology and pathology; immunochemistry and immunobiology. Manuscripts are solicited which correlate findings in the biochemical and biophysical fields with morphological, cytological and physiological knowledge.

Discoveries resulting from advances in, and application of, modern biological and medical techniques to cytology are particularly welcome. So also are cytochemical papers which contribute to an understanding of cell organization and to the study of organic fine structure.

The subscription rate for 1997 will be £395.00 sterling

#### **BIOMEDICAL LETTERS**

is an international research journal, established in 1976 as *Microbios Letters*, having the fundamental aim of accelerated publication, and distribution to a worldwide readership. It is intended for short and preliminary biomedical communications, but may include some longer papers and reviews. In general manuscripts should not exceed 5,000 words in length and include only one or two Tables and/or Figures.

*BIOMEDICAL LETTERS* is primarily designed for the publication of medical research papers. Clinical studies will be considered, and papers in such fields as cellular pharmacology, virology, bacteriology, biochemistry, immunology, molecular biology, biochemical genetics, biophysics, haematology, physiology. Manuscripts on neuroscience, radiation biology and cancer research, will be particularly welcome.

The subscription rate for 1997 will be £200.00 sterling

#### Manuscripts

To enable the Executive Editors to plan the publishing programme of forthcoming issues, the following information will be much appreciated:

(a) MI (b) C`	to submit a paper for publication in CROBIOS YTOBIOS OMEDICAL LETTERS	Tick box • •		
	send me a free copy of the leaflet d 'Information for contributors'	•		
The proba	ble title of the paper will be:			
I confirm that this manuscript will be based on original, unpublished research, and I understand that all papers are subject to peer reviewing procedures before acceptance. The approximate date of submission will be:				
Name				
Status				
Address				

.....

.....

.....

Please complete and return to the address below:

THE FACULTY PRESS 88 Regent Street Cambridge C82 1DP Great Britain